Skip to main navigation menu Skip to main content Skip to site footer


Vol. 146 No. 3132 (2016)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough

  • Markus Mohaupt
Cite this as:
Swiss Med Wkly. 2016;146:w14345


  1. Koskinas K, Wilhem M, Windecker S. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Med Wkly. 2016;146:w14333.
  2. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–88.
  3. Yue P, Averna M, Lin X, Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat. 2006;27(5):460–6.
  4. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514–23.
  5. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102.